The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Open accessAbstract
BACKGROUND: Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy. METHODS: In part 1, the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of body weight. In part 2, the dose-expansion phase, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogram, administered once weekly (8 doses), twice monthly (8 doses), and monthly for up to 24 months. End points included safety, efficacy, and pharmacokinetics. RESULTS: No maximum tolerated dose was identified in part 1. In part 2, the median time since diagnosis was 5.7 years. Patients had received a median of four prior treatments; 79% of the patients had disease that was refractory to the last therapy received (64% had disease refractory to proteasome inhibitors and immunomodulatory drugs and 64% had disease refractory to bortezomib and lenalidomide), and 76% had received autologous stem-cell transplants. Infusion-related reactions in part 2 were mild (71% of patients had an event of any grade, and 1% had an event of grade 3), with no dose-dependent adverse events. The most common adverse events of grade 3 or 4 (in ≥ 5% of patients) were pneumonia and thrombocytopenia. The overall response rate was 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better, including 2 with a complete response and 2 with a very good partial response) and 10% in the cohort that received 8 mg per kilogram (3 had a partial response). In the cohort that received 16 mg per kilogram, the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 8.1), and 65% (95% CI, 28 to 86) of the patients who had a response did not have progression at 12 months. CONCLUSIONS: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma. (Funded by Janssen Research and Development and Genmab; ClinicalTrials.gov number, NCT00574288.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab is active in relapsed, refractory multiple myeloma.85”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy 9,10 and combination therapy, 18,19,32 were mostly of grade 1 or 2, and usually occurred during the first infusion.”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationKumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citationSiegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 664
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma
Lin, P. Y., Owens, R., Tricot, G. J. K., & Wilson, C. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/74r4tb90buwh27jx · Cited by 454
Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
Self-citationZonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma
Sorgiovanni, I., Giudice, M. L. D., Galimberti, S., & Buda, G. (2025) · Pharmaceuticals · doi:10.3390/ph18020145 · Cited by 3
The first case of Teclistamab interference with serum electrophoresis and immunofixation
Kadkhoda, K., Faiman, B. M., Valent, J. N., Albahra, S., & Boyert, N. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0382 · Cited by 2
Branagan, A. R., Mo, C. C., Lei, M. M., Gustine, J. N., Yee, A. J., O’Donnell, E., Castillo, J. J., Nadeem, O., Flynn, C., Bernstein, Z. S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016513 · Cited by 2
Self-citationWang, C., Xu, Z., Jiang, M., Chen, Y., & Yu, L. (2025) · Cancers · doi:10.3390/cancers17203349 · Cited by 2
Yi, J. H., Yoon, D. H., & Kım, K. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.11.003 · Cited by 2
Should immunologic strategies be incorporated into frontline ALL therapy?
Rank, C. U., & Stock, W. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.09.015 · Cited by 2
Peng, Y., Li, Y., Lo, H. H., Law, B. Y. K., & Wong, V. K. W. (2020) · Springer eBooks · doi:10.1007/978-981-15-5159-8_6 · Cited by 2
Tai, W., Wahab, A., Franco, D., Shah, Z., Ashraf, A., Abid, Q., Mohammed, Y. N., Lal, D., & Anwer, F. (2022) · Antibodies · doi:10.3390/antib11020022 · Cited by 2
Repositioning Drugs for Systemic Lupus Erythematosus
Grammer, A. C., Ryals, M. M., Catalina, M. D., & Lipsky, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801917-7.00066-8 · Cited by 2
Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins
Schieferdecker, A., Shoshani, O., Westner, B., Zipori, D., Fehse, B., Kröger, N. M., & Ayuk, F. A. (2016) · Oncotarget · doi:10.18632/oncotarget.11489 · Cited by 2
Drugs That Act on the Immune System
Lindfelt, T. A. (2016) · Side effects of drugs annual · doi:10.1016/bs.seda.2016.08.021 · Cited by 2
Clinical trials evaluating potential therapies for light chain (AL) amyloidosis
Muchtar, E., & Gertz, M. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1341834 · Cited by 2
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
Bhutani, D., & Zonder, J. A. (2017) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s82444 · Cited by 2
Les points chauds de l’actualité en 2017. Une sélection du comité de rédaction du Bulletin du Cancer
Vignot, S., André, T., Caux, C., Bouleuc, C., Évrard, S., Gonçalvès, A., Lacroix‐Triki, M., Magné, N., Massard, C., Mazeron, J., et al. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.11.006 · Cited by 2
Optimizing therapy in bortezomib-exposed patients with multiple myeloma
Migkou, M., Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1479637 · Cited by 2
Guérison du myélome multiple : un objectif envisageable à court terme ?
Facon, T. T. F. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30260-2 · Cited by 2
Daratumumab-induced pancytopenia: collateral damage from the silver bullet
Grainger, B. T., Hanna, M., & Henderson, R. A. (2020) · Pathology · doi:10.1016/j.pathol.2020.04.008 · Cited by 2
Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
Plesner, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051002 · Cited by 2
Self-citationKim, J., Park, S., Yoon, J., Lee, S., Kim, H., & Min, C. (2022) · Blood Research · doi:10.5045/br.2022.2021183 · Cited by 2
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia
Amaador, K., Kersten, M. J., Minnema, M. C., & Vos, J. M. I. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2131423 · Cited by 2
Self-citationSharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 3
Chiu, L., Kuo, C.-Y., Ma, M., Liao, C., Liu, H.-L., & Wang, M. (2023) · Journal of Cancer Research and Practice · doi:10.4103/ejcrp.ejcrp-d-22-00032 · Cited by 2
Putting the best foot forward when treating newly diagnosed multiple myeloma
Lim, S., & Spencer, A. G. (2023) · Internal Medicine Journal · doi:10.1111/imj.16034 · Cited by 2
A look at treatment strategies for relapsed multiple myeloma
Cetani, G., Boccadoro, M., & Oliva, S. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1477594 · Cited by 2
Yu, T., Qiao, C., Lv, M., & Tang, L. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0524-8 · Cited by 2
Hosokawa, M., Kashiwagi, H., Nakayama, K., Sakuragi, M., Nakao, M., Morikawa, T., Kiyokawa, T., Aochi, H., Nagamine, K., Shibayama, H., et al. (2019) · Japanese Journal of Transfusion and Cell Therapy · doi:10.3925/jjtc.65.600 · Cited by 2
Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
Verkleij, C. P. M., Bruins, W. S. C., Zweegman, S., & van de Donk, N. W. C. J. (2021) · Hemato · doi:10.3390/hemato2010007 · Cited by 2
Williams, G. R., Butala, A. A., Manjunath, S. H., Maxwell, R., Anstadt, E. J., Waxman, A. J., Jones, J., Plastaras, J. P., & Paydar, I. (2021) · Advances in Radiation Oncology · doi:10.1016/j.adro.2021.100720 · Cited by 2
Gopal, V., & Dubashi, B. (2020) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_263_19 · Cited by 2
Resistance to daratumumab in patients with multiple myelomaPreprint
Iversen, K. F. (2024) · doi:10.22541/au.171345600.04580861/v1 · Cited by 2
Patır, P., Önkibar, N., Subari, S., & Eşkazan, A. E. (2024) · Transfusion · doi:10.1111/trf.17716 · Cited by 1
Major-Monfried, H., Hosszu, K., McAvoy, D. P., Vallone, A., Shukla, N. N., Gillio, A. P., Spitzer, B. G., Kung, A. L., Cancio, M., Curran, K. J., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.01.005 · Cited by 1
The importance of removing interference caused by Darzalex® (daratumumab) in pre-transfusion testing
Dilberović, A., Kola, L., & Kola, I. (2024) · Journal of Health Sciences · doi:10.17532/jhs.2023.2612 · Cited by 1
Wolstenhulme, F., Bibby, I., Cole, M., Grixti, L., McGregor, N., Bradley, P., Maier, R. H., Walker, J., Pearce, S. H. S., & Wason, J. M. S. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079158 · Cited by 1
Collier‐Bain, H. D., Emery, A., Brown, F. F., Causer, A. J., Oliver, R., Eddy, R., Leach, S., Graby, J., Augustine, D. X., Moore, S. E., et al. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100865 · Cited by 2
The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium
McGovern, D., Jones, R. B., Jayne, D. R. W., & Smith, R. (2025) · Drugs · doi:10.1007/s40265-024-02143-z · Cited by 1
Park, S., Choi, S., Jung, S., Han, S., Lee, C., Han, J., Kim, S., Kım, K., & Min, C. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2025.046 · Cited by 1
Liang, Y., Chang, J. K., Gao, Y., Sun, L., Yue, Z., Meng, L., Guo, C., & Zhang, Y. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06424-9 · Cited by 1
Overcome Daratumumab’ severe reaction with desensitization in relapsed multiple myeloma
Nguyen, T. L., Phan, T., Vu, M., Huynh, K., Gyu, Y. H., Nguyen, T. D., Phan, L., Nguyen, T. D., & Nguyen, D. V. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251356918 · Cited by 1
Llinares, J., Toribio-Castelló, S., García, L. F., Iglesias, T., Heredero, A., Rebollo, P., Ricote, I., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.07.008 · Cited by 1
CAR-T cell therapy for multiple myeloma: An update on the current state and future potential
Pophali, P. A., Rosenblatt, J. M., & Avigan, D. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101659 · Cited by 1
Current Status of Molecularly Targeted Therapeutics in Blood Cancers
Kumala, C., Vu, L., & Fandy, T. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110512 · Cited by 1
Immune mechanisms and immunomodulatory therapies in steroid-resistant nephrotic syndrome
Deng, J., Zhu, L., & Zhu, X. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2556486 · Cited by 1
Li, X., Wang, H., Li, Y., Zhou, J. W., Yang, N., Wei, X., Cai, X., Xiao, Z., Du, J., & Zeng, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-15250-1 · Cited by 1
Liu, Y., Zhang, Y., Yang, W., Du, H., Sun, S., Li, Z., & Zong, D. (2025) · Pharmaceuticals · doi:10.3390/ph19010018 · Cited by 1
CD38-Targeted Molecular Imaging Probes for Multiple Myeloma: Advances, Challenges, and Opportunities
Zheng, M., Zhang, K., Mu, H., Liu, Q., Ge, S., Shan, Y., Ma, H., Peng, X., Li, S., Zhang, H., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01232 · Cited by 1
Gozzetti, A., Pacelli, P., Caroni, F., Raspadori, D., Bestoso, E., Antonioli, E., Buda, G., Ciofini, S., Santoni, A., Puccetti, L., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70448 · Cited by 1
Шелехова, Т. В., Kumar, J., Apte, S., Osipov, I. S., Misyurina, E. N., Doronin, V., Konstantinova, T. S., Бакиров, Б. А., Proidakov, A. V., Усс, А. Л., et al. (2026) · Clinical oncohematology · doi:10.21320/2500-2139-2026-19-2-119-130 · Cited by 1
New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review
Votyakova, O. M. (2017) · Clinical oncohematology · doi:10.21320/2500-2139-2017-10-4-425-434 · Cited by 1
Treatment of Patients in First or Second Relapse
Yee, A. J., & Raje, N. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-61872-2_5 · Cited by 1
DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
Владимирович, Р. В., & Канаева, М. Л. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-14-94-102 · Cited by 2
Qadri, S. M., Donkor, D. A., Yan, M. T. S., Ning, S., Branch, D. R., Seghatchian, J., & Sheffield, W. P. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.04.011 · Cited by 1
Utilisation du daratumumab dans le myélome multiple
Croizier, C., & Bailly, S. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.09.003 · Cited by 1
The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab
Lapietra, G., Fazio, F., & Petrucci, M. T. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95406 · Cited by 1
[Progress in the treatment of multiple myeloma with daratumumab].
Lu, J. (2021) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2021.03.016 · Cited by 1
Gupta, A. M., Ojha, S. K., Tirlotkar, A., & Sathyan, V. (2021) · Global Journal of Transfusion Medicine · doi:10.4103/gjtm.gjtm_50_20 · Cited by 1
The evolving role and utility of off-label drug use in multiple myeloma
Stoeckle, J. H., Davies, F. E., Williams, L. S., Boyle, E. M., & Morgan, G. J. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00050 · Cited by 1
Compatibility testing and blood transfusion in the treatment with anti-CD38 monoclonal antibody
Raos, M., Bojanić, I., Bašić‐Kinda, S., Batinić, J., & Ćepulić, B. G. (2021) · Liječnički vjesnik · doi:10.26800/lv-142-11-12-56 · Cited by 1
Recent developments on the application of molecular probes in multiple myeloma: Beyond [18F]FDG
Zhang, S., Shang, J., Ye, W., Zhao, T., Xu, H., Zeng, H., & Wang, L. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.920882 · Cited by 1
Ryabukhina, Y. E., Abbasbeyli, F. M., Zeynalova, P. A., Тимофеева, О. Л., Александровна, К. Н., & Жуков, А. Г. (2022) · MD-Onco · doi:10.17650/2782-3202-2022-2-3-28-35 · Cited by 1
Treatment and Disease-related Complications in Multiple Myeloma
Kayyali, L., Diak, Z. A., Diak, O. A., & Krawczyk, J. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106160 · Cited by 1
Skvortsova, N. V., Vorontsova, E. V., Нечунаева, И. Н., Voropaeva, E. N., Kovynev, I. B., & Pospelova, T. I. (2023) · JOURNAL of SIBERIAN MEDICAL SCIENCES · doi:10.31549/2542-1174-2023-7-2-90-113 · Cited by 1
Case 29-2023: A 34-Year-Old Woman with Abdominal Distention and Acute Kidney Injury
Jagannath, S., Anderson, M., Yee, A. J., & Hasserjian, R. P. (2023) · New England Journal of Medicine · doi:10.1056/nejmcpc2027091 · Cited by 1
Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman
Asif, S. (2023) · ONCOLOGY · doi:10.46883/2023.25921005 · Cited by 1
van Nieuwenhuijzen, N., Cuenca, M., Abbink, L., Jak, M., Peperzak, V., & Minnema, M. C. (2023) · eJHaem · doi:10.1002/jha2.824 · Cited by 1
Self-citationMohammadi-Oroujeh, M., Mehreen, A., & Grinblatt, D. L. (2023) · Case Reports in Hematology · doi:10.1155/2023/6669174 · Cited by 1
Pitaro, M., Antonini, G., Arcovito, A., Buccisano, F., Lauro, A. D., Consalvo, M. I., Gallo, V., Giacon, N., Mangiatordi, G. F., Pacelli, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1520103 · Cited by 1
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
Galušić, D., Krečak, I., Blaslov, V., Anđela, K. O., Valković, T., & Bašić‐Kinda, S. (2025) · Biomedicines · doi:10.3390/biomedicines13010207 · Cited by 1
Zhou, H., Huang, Z., Fang, B., Jing, H., Xia, Z., Song, Y., Cai, Z., An, G., Ling, Q., Bao, L., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27573 · Cited by 1
Monoklonalne przeciwciała w szpiczaku plazmocytowym – przełom w terapii
Olszewska‐Szopa, M., & Jurczyszyn, A. J. (2015) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2015.11.003 · Cited by 1
Drug Monographs: Daratumumab and Osimertinib
Solimando, D. A., & Waddell, J. A. (2016) · Hospital Pharmacy · doi:10.1310/hpj5104-288 · Cited by 1
Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
Kalis, J. A. (2017) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2017.8.1.7 · Cited by 1
Unmassked: Single-Cell Profiling of Immune Cell Populations in Tumors
Varadarajan, N. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.024 · Cited by 1
Treatment of Relapsed/Refractory Patients with Multiple Myeloma
Laubach, J. P., Moreau, P., Dimopoulos, M. A., & Richardson, P. G. G. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_5 · Cited by 1
Self-citationTreatment of Transplant Eligible Patients with Multiple Myeloma
Sonneveld, P., Einsele, H., Brioli, A., & Cavo, M. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_3 · Cited by 1
Dinner, S. N., Dunn, T. J., Price, E. A., Coutre, S. E., Gotlib, J. R., Berube, C., Kaufman, G. P., Medeiros, B. C., & Liedtke, M. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2468-5 · Cited by 1
Gastrointestinal manifestations of amyloidosis
Qi, F., Zhang, Y., Ji, Y., & Jiang, Y. L. (2019) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v27.i4.260 · Cited by 1
Uslu, A., Seval, G. C., Merter, M., Dalva, K., & Beksaç, M. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.11.017 · Cited by 1
A Case of Presyncope and Bradycardia With Daratumumab Infusion
Yeager, J., & Poudel, A. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001339 · Cited by 1
Leleu, X. P., Chari, A., Richard, S., Khurana, M., Yusuf, A., & Usmani, S. Z. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1955343 · Cited by 1
Multiple Myeloma: Risk Stratification and Toxicity Management
Richards, T., & Lee, H. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.3.10 · Cited by 1
An update on novel multiple myeloma targets
Offidani, M., Corvatta, L., Morè, S., Manieri, V. M., & Olivieri, A. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2085088 · Cited by 1
Case 20-2022: A 25-Year-Old Man with Vision Changes
DeFilipp, Z. M., Rodriguez, K., & Ferry, J. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmcpc2115854 · Cited by 1
VERY‐LARGE‐SCALE PRODUCTION OF MONOCLONAL ANTIBODIES IN PLANTS
Buyel, J. F., Twyman, R. M., & Fischer, R. (2017) · doi:10.1002/9781119126942.ch30 · Cited by 1
Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab
Janmaat, M. L., van de Donk, N. W. C. J., van Bueren, J. J. L., Ahmadi, T., Sasser, A. K., Jansson, R. K., Lokhorst, H. M., & Parren, P. W. H. I. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch7 · Cited by 1
Self-citationΠ-π Stacked Polymeric Micelles as Carriers of Anticancer Therapeutics for Hematological Malignancies
Varela-Moreira, A. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/145 · Cited by 1
Reply to G. R. Mohyuddin et al and A. Garfall et al
Richardson, P. G. G., & Moreau, P. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02081 · Cited by 1
Self-citationValue Passing in Stochastically Timed Process Algebras: A Symbolic Approach based on Lookahead
Bernardo, M. (2000) · Cited by 1
Prodrugs: Strategic Deployment, Metabolic Considerations, and Chemical Design Principles
Erhardt, P., Khupse, R. S., Sarver, J. G., & Kress, B. J. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc157.pub2 · Cited by 1
In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancerPreprint
Deng, J., Peng, D. H., Fenyö, D., Yuan, H., Lopez, A., Levin, D. S., Meynardie, M., Quinteros, M., Ranieri, M., Sahu, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.18.537350 · Cited by 4
Anti-CD38 Immunotherapy for Multiple Myeloma
Williams, M. E. (2015) · Journal watch · doi:10.1056/nejm-jw.na39718
Life beyond bortezomib: increasing treatment options in refractory myeloma
Chakraborty, R., & Gertz, M. A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1153090
New Pharmaceutical Agents in Oncology
Cambareri, C., Nobre, C. F., & Tuttle, L. A. (2016) · Physician Assistant Clinics · doi:10.1016/j.cpha.2016.03.012
Advances in Immunotherapy for Hematological Malignancies
Miura, K., Hatta, Y., & Takei, M. (2016) · Journal of Nihon University Medical Association · doi:10.4264/numa.75.4_167
Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016
Tandon, N., & Kumar, S. K. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0796-x
Addition eines CD38-Antikörpers zur Therapie des multiplen Myeloms
Teipel, R., & Röllig, C. (2017) · Info Onkologie · doi:10.1007/s15004-017-5698-4
Immune Therapy for Multiple Myeloma
Bishop, M. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.08.065
RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms
Weisel, K. C., & Kanz, L. (2017) · Info Onkologie · doi:10.1007/s15004-017-5793-6
Retracted
Metadata
- Authors
- Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N. W. C. J., Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L., Brun, N., & Richardson, P. G.
- Affiliations
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Harvard University (US)
- Karolinska University Hospital (SE)
- Lund University (SE)
- University Medical Center Utrecht (NL)
- University of Turin (IT)
- Janssen Research & Development (United States) (US)
- Genmab (Denmark) (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-09-24
- Volume
- 373
- Issue
- 13
- Pages
- 1207-1219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1902692042
- Semantic Scholar
- c731f1036338cb22a95a42420cb4ccf650d6c359
- Cited by
- 1,117
- References
- 27
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 63 · 2023: 87 · 2022: 83 · 2021: 134 · 2020: 131 · 2019: 108 · 2018: 129 · 2017: 125 · 2016: 143 · 2015: 14
- FWCI
- 107.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, daratumumab, CD38, monoclonal antibodies, relapsed/refractory multiple myeloma, monotherapy, dose escalation, progression-free survival, overall response rate, infusion reactions, pharmacokinetics, autologous stem cell transplantation, lenalidomide-refractory disease, bortezomib-refractory disease, pneumonia, thrombocytopenia, complete response, very good partial response
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, Pneumonia, Thrombocytopenia, Disease-Free Survival, Drug Resistance, Neoplasm, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
